Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 6Lung Neoplasms 3Recurrence 2Neoplasms 2Melanoma 2Glioblastoma 2Vulvar Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Carcinoma, Anaplastic 1Skin Neoplasms 1Rectal Neoplasms 1Penile Neoplasms 1Mesothelioma, Malignant 1Head and Neck Neoplasms 1Gliosarcoma 1Glioma 1Ependymoma 1Disease Progression 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Renal Cell 1Carcinoma, Merkel Cell 1Carcinoma 1Advanced Squamous Non-Small Cell Lung Cancer 1Adenocarcinoma 1

Interventions

cemiplimab 1X-Rays 1Specimen Handling 1Photons 1Magnetic Resonance Spectroscopy 1Actinium 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Gliosarcoma × cemiplimab × Clear all
NCT07422363 2026-05-13

Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma

National Cancer Institute (NCI)

Phase 1 Not yet recruiting
30 enrolled
CNSSarcoma

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡